The global preclinical CRO market size was estimated at USD 6.7 billion in 2025 and is projected to reach USD 12.8 billion by 2033, growing at a CAGR of 8.4% from 2026 to 2033. The market growth is driven by economic outsourcing, regulatory mandates, and scientific complexities, which, in turn, make preclinical CROs a critical component of the early-stage drug development process.
Besides, the rising demand for toxicology, pharmacology, and efficacy studies is expected to drive market growth. The outsourcing trends of preclinical research, particularly among biotech and biopharma companies seeking to minimize fixed infrastructure costs, shorten development timelines, and access specialized expertise, are expected to significantly contribute to future growth. Moreover, increasing complexity in drug development, higher biopharma R&D investments, and stringent regulations requiring Good Laboratory Practice (GLP)-compliant studies are influencing the market growth. Thus, these factors are driving manufacturers to rely more on CROs to optimize costs and reduce operational burdens, thereby fueling market growth.
The market is anticipated to grow owing to growing R&D offshoring and the rising outsourcing trend, increasing demand for personalized medicine and advanced therapeutics, increasing pharmaceutical R&D investments, and the integration of translational biomarkers into preclinical studies, among others.
The trend of R&D offshoring is attributed to structural shifts in the pharmaceutical and biotechnology industries. Since the R&D costs for developing new drugs are high, coupled with longer discovery timelines and increasing complexity, the manufacturers are relying on outsourcing to CROs at cost-effective locations for conducting preclinical studies. This R&D offshoring allows companies to leverage the availability of highly skilled resources, advanced infrastructure, and laboratory capacity at significantly lower cost than in the U.S. and Europe, especially for smaller and mid-sized biopharma companies without internal capabilities, and for large pharma to improve capital efficiency.
The developing markets, including India and China, have emerged as major centers with GLP-compliant facilities, integrated service offerings, and cost advantages of 30-60% over other locations. The CROs in these countries offer comprehensive capabilities, including discovery, toxicology, DMPK, and in vivo studies, enabling faster, more flexible studies. Moreover, the development of hybrid R&D operations, including both onshore strategy and offshore execution, has further strengthened this trend.
In addition, strategic collaborations and initiatives undertaken by the companies are further bolstering the outsourcing growth. For instance, in February 2026, Syngene International signed a partnership agreement with Johns Hopkins University, leveraging discovery and preclinical capabilities to advance early-stage research into clinical candidates. Similarly, in January 2026, Syngene International extended its existing collaboration with Bristol Myers Squibb through 2035, providing a dedicated R&D extension including discovery, preclinical, and manufacturing capabilities. Such initiatives are likely to propel the market growth over the forecast period.
Furthermore, the demand for personalized medicine and advanced therapeutics is driving the growth of preclinical CROs, driven by factors such as the rising need for new drug discoveries to combat the increasing incidence of chronic illnesses worldwide, as well as companies' strategic initiatives and technology integration. For instance, in March 2026, NJ Bio and Ajinomoto Bio-Pharma Services partnered to enhance NJ Bio's capabilities in antibody-drug conjugate development by integrating the AJICAP technology into its workflow. This will allow modification of the antibody at a site-specific level, thereby improving the stability, efficacy, and pharmacokinetics of the antibody-drug conjugate.
Similarly, in March 2026, Eli Lilly and Insilico Medicine partnered by signing an agreement valued at up to USD 2.75 billion to enhance drug discovery using artificial intelligence technology. The partnership agreement grants Eli Lilly exclusive global rights to the development and commercialization of selected oral drug candidates currently in preclinical development. In return, Insilico Medicine will receive royalty payments and leverage its AI technology to discover new disease targets and speed up its pipeline. Thus, an increase in the demand for advanced therapeutics and personalized medicines is likely to impel the market’s growth over the coming years.
Besides, the rising demand for toxicology, pharmacology, and efficacy studies is expected to drive market growth. The outsourcing trends of preclinical research, particularly among biotech and biopharma companies seeking to minimize fixed infrastructure costs, shorten development timelines, and access specialized expertise, are expected to significantly contribute to future growth. Moreover, increasing complexity in drug development, higher biopharma R&D investments, and stringent regulations requiring Good Laboratory Practice (GLP)-compliant studies are influencing the market growth. Thus, these factors are driving manufacturers to rely more on CROs to optimize costs and reduce operational burdens, thereby fueling market growth.
The market is anticipated to grow owing to growing R&D offshoring and the rising outsourcing trend, increasing demand for personalized medicine and advanced therapeutics, increasing pharmaceutical R&D investments, and the integration of translational biomarkers into preclinical studies, among others.
The trend of R&D offshoring is attributed to structural shifts in the pharmaceutical and biotechnology industries. Since the R&D costs for developing new drugs are high, coupled with longer discovery timelines and increasing complexity, the manufacturers are relying on outsourcing to CROs at cost-effective locations for conducting preclinical studies. This R&D offshoring allows companies to leverage the availability of highly skilled resources, advanced infrastructure, and laboratory capacity at significantly lower cost than in the U.S. and Europe, especially for smaller and mid-sized biopharma companies without internal capabilities, and for large pharma to improve capital efficiency.
The developing markets, including India and China, have emerged as major centers with GLP-compliant facilities, integrated service offerings, and cost advantages of 30-60% over other locations. The CROs in these countries offer comprehensive capabilities, including discovery, toxicology, DMPK, and in vivo studies, enabling faster, more flexible studies. Moreover, the development of hybrid R&D operations, including both onshore strategy and offshore execution, has further strengthened this trend.
In addition, strategic collaborations and initiatives undertaken by the companies are further bolstering the outsourcing growth. For instance, in February 2026, Syngene International signed a partnership agreement with Johns Hopkins University, leveraging discovery and preclinical capabilities to advance early-stage research into clinical candidates. Similarly, in January 2026, Syngene International extended its existing collaboration with Bristol Myers Squibb through 2035, providing a dedicated R&D extension including discovery, preclinical, and manufacturing capabilities. Such initiatives are likely to propel the market growth over the forecast period.
Furthermore, the demand for personalized medicine and advanced therapeutics is driving the growth of preclinical CROs, driven by factors such as the rising need for new drug discoveries to combat the increasing incidence of chronic illnesses worldwide, as well as companies' strategic initiatives and technology integration. For instance, in March 2026, NJ Bio and Ajinomoto Bio-Pharma Services partnered to enhance NJ Bio's capabilities in antibody-drug conjugate development by integrating the AJICAP technology into its workflow. This will allow modification of the antibody at a site-specific level, thereby improving the stability, efficacy, and pharmacokinetics of the antibody-drug conjugate.
Similarly, in March 2026, Eli Lilly and Insilico Medicine partnered by signing an agreement valued at up to USD 2.75 billion to enhance drug discovery using artificial intelligence technology. The partnership agreement grants Eli Lilly exclusive global rights to the development and commercialization of selected oral drug candidates currently in preclinical development. In return, Insilico Medicine will receive royalty payments and leverage its AI technology to discover new disease targets and speed up its pipeline. Thus, an increase in the demand for advanced therapeutics and personalized medicines is likely to impel the market’s growth over the coming years.
Global Preclinical CRO Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global preclinical CRO market report based on service, development stage, indication, model, end use, and region.Service Outlook (Revenue, USD Million, 2021-2033)
- Bioanalysis and DMPK studies
- In vitro ADME
- In-vivo PK
- Toxicology Testing
- GLP
- Non-GLP
- Compound Management
- Process R&D
- Custom Synthesis
- Others
- Chemistry
- Medicinal Chemistry
- Computation Chemistry
- Safety Pharmacology
- Others
Development Stage Outlook (Revenue, USD Million, 2021-2033)
- Target Discovery
- Preclinical Optimization, Efficacy & PK/PD
- IND-Enabling Safety (GLP)
- Bioanalysis & Analytics
Indication Outlook (Revenue, USD Million, 2021-2033)
- Oncology
- CNS
- Infectious Diseases
- Cardiovascular Diseases
- Metabolic Disorders
- Rare Diseases
- Others
Model Outlook (Revenue, USD Million, 2021-2033)
- In Vitro
- In Vivo
- Ex Vivo
End Use Outlook (Revenue, USD Million, 2021-2033)
- Pharmaceutical and Biopharmaceutical Companies
- Medical Device Companies
- Academic and Research Institutes
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
- Kuwait
- Qatar
- Oman
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Research Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Preclinical CRO Market Variables, Trends & Scope
Chapter 4. Preclinical CRO Market: Service Estimates & Trend Analysis
Chapter 5. Preclinical CRO Market: Development Stage Estimates & Trend Analysis
Chapter 6. Preclinical CRO Market: Indication Estimates & Trend Analysis
Chapter 7. Preclinical CRO Market: Model Estimates & Trend Analysis
Chapter 8. Preclinical CRO Market: End Use Estimates & Trend Analysis
Chapter 9. Preclinical CRO Market: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Eurofins Scientific
- ICON plc
- WuXi AppTec
- Medpace Holdings, Inc.
- Charles River Laboratories
- PPD (Thermo Fisher Scientific, Inc.)
- SGS SA (SGS Société Générale de Surveillance SA.)
- Intertek Group plc (IGP)
- Labcorp
- Crown Bioscience
- Scantox
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 6.7 Billion |
| Forecasted Market Value ( USD | $ 12.8 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
